L'intérêt à découvert pour ImmunityBio donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de ImmunityBio. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

ImmunityBio (NASDAQ:IBRX) Stock, Rapport sur les intérêts à découvert

ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

ImmunityBio Inc

Barclays analyst Jeffrey Bernstein maintains BJ's Restaurants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) with a Underweight and raises the price target from $31 to $33.

News

Price Target

Analyst Ratings

BJRI

Barclays Maintains Underweight on BJ's Restaurants, Raises Price Target to $33

Barclays analyst Peter Lawson maintains Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) with a Overweight and lowers the price target from $32 to $16.

ARVN

Barclays Maintains Overweight on Arvinas, Lowers Price Target to $16

In a strategic move,&nbsp;Alibaba Group Holding&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) has advanced the rollout of its rapid-delivery service, Taobao Instant Commerce. This accelerates the rivalry with&nbsp;JD.com&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)and&nbsp;Meituan (OTC: MPNGY).
What Happened: The service, <a href="https://www.benzinga.com/25/04/45105930/alibaba-instant-commerce-delivery">initially slated</a> for a May 6 launch in 50 key Chinese cities, offers quick delivery of food, groceries, electronics, and apparel. The expedited launch, announced on Weibo on Friday, is a response to the increasing local demand for swift and cost-effective delivery, a vital component of urban living in China, <a href="https://www.scmp.com/tech/big-tech/article/3308856/alibaba-launches-taobao-fast-delivery-service-ahead-time-challenge-jdcom-meituan?utm_medium=email&amp;utm_source=cm&amp;utm_campaign=enlz-china&amp;utm_content=20250502&amp;tpcc=enlz-china&amp;UUID=03787f75-eeb3-47ab-bf96-c3d147adf8af&amp;next_article_id=3308793&amp;article_id_list=3308856,3308793&amp;tc=3">reported</a> South China Morning Post.
Alibaba&#8217;s latest service aims to deliver&nbsp;online food orders and&nbsp;consumer goods in under an hour. This rapidity is facilitated by China&#8217;s extensive delivery workforce and the application of advanced algorithms in warehousing, mapping, and matching.
The new service—which spans categories like food, groceries, electronics, and clothing—represents an upgrade to Alibaba's original local delivery system, with order fulfillment managed by its food delivery arm, Ele.me.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/05/45158172/amazon-ceo-andy-jassy-predicts-pandemic-like-consumer-shifts-says-company-is-maniacally-focused-on-keeping-prices" target="_blank" rel="noreferrer noopener">Andy Jassy Predicts Pandemic-Like Consumer Shifts, Says Amazon Is &#8216;Maniacally Focused&#8217; On Keeping Prices Low</a>
Why It Matters: This move comes on the heels of Alibaba&#8217;s recent advancements in artificial intelligence. Earlier this week, Alibaba <a href="https://www.benzinga.com/25/04/45057716/alibabas-qwen-3-launch-takes-aim-at-deepseeks-disruption-and-baidus-ernie-turbo-models">introduced </a>Qwen 3, its most sophisticated AI model to date, featuring hybrid reasoning capabilities.
This development is part of a larger trend of Chinese tech giants <a href="https://www.benzinga.com/markets/asia/25/04/45015548/baidu-goes-aggressive-chinas-in-ai-price-war-with-alibaba-deepseek">aggressively investing </a>in AI to expand their market share. Recently, Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) lowered its AI model prices by nearly 80% to rival Alibaba and DeepSeek in China&#8217;s growing AI price war.
With consumer spending in China remaining sluggish, e-commerce growth has also decelerated, prompting major platform operators to intensify competition through consumer subsidies and enhanced services. Notably, Alibaba&#8217;s early launch of Taobao Instant Commerce underscores the company&#8217;s commitment to leveraging technology to enhance customer experience and stay ahead in the competitive market.
During Friday pre-market, ADR of JD.Com, Alibaba and Baidu climbed 4.6%, 3.97% and 2.68%, respectively, as Chinese Ministry of Commerce stated that it is assessing U.S. trade proposals and is open for talks. 
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/tech/25/04/45057119/anthony-scaramucci-once-purchased-1200-worth-of-microsoft-stock-for-his-son-in-1992-and-then-forgot-about-it-three-decades-later-it-quietly-turned-into-a-small-fortune-that-he-didn" target="_blank" rel="noreferrer noopener">Anthony Scaramucci Once Purchased $1,200 Worth Of Microsoft Stock For His Son In 1992 And Then Forgot About It — Three Decades Later, It Quietly Turned Into A Small Fortune That He Didn&#8217;t Know He Ow</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Tech

BABA

BIDU

MPNGY

Alibaba Accelerates Taobao Instant Commerce Launch, Heats Up Rivalry With JD.com, Meituan

Barclays analyst Ross Sandler maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Overweight and lowers the price target from $265 to $240.

AMZN

Barclays Maintains Overweight on Amazon.com, Lowers Price Target to $240

Barclays analyst Gaurav Jain maintains Altria Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) with a Underweight and raises the price target from $46 to $49.

Barclays Maintains Underweight on Altria Group, Raises Price Target to $49

Barclays analyst Mario Lu maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Underweight and lowers the price target from $120 to $103.

ABNB

Barclays Maintains Underweight on Airbnb, Lowers Price Target to $103

<a href="https://www.ft.com/content/bc4465d2-59ae-41fd-8b1a-8c39a9091cd4" title="https://www.ft.com/content/bc4465d2-59ae-41fd-8b1a-8c39a9091cd4">https://www.ft.com/content/bc4465d2-59ae-41fd-8b1a-8c39a9091cd4</a>

'Jeff Bezos To Sell Up To $4.75bn In Amazon Stock'

Barclays analyst Duffy Fischer maintains Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) with a Overweight and lowers the price target from $355 to $325.

Barclays Maintains Overweight on Air Products & Chemicals, Lowers Price Target to $325

Barclays analyst Alex Scott maintains American International Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) with a Overweight and raises the price target from $92 to $93.

Barclays Maintains Overweight on American International Gr, Raises Price Target to $93

Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) reported quarterly losses of $(0.63) per share. This is a 16 percent increase over losses of $(0.75) per share from the same period last year. The company reported $6.55 million in sales this quarter. This is a 0.27 percent decrease over sales of $6.57 million the same period last year.

Earnings

RYDE

Ryde Group FY GAAP EPS $(0.63) Up From $(0.75) YoY, Sales $6.55M Down From $6.57M YoY

Cantor Fitzgerald analyst Deepak Mathivanan maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Underweight and lowers the price target from $101 to $100.

Cantor Fitzgerald Maintains Underweight on Airbnb, Lowers Price Target to $100

Cigna Group&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) on Friday reported first-quarter 2025 revenue of $65.45 billion, beating analyst <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimates of $60.39 billion</a>.
Sales increased 14% year over year, reflecting the growth of existing client relationships and strong specialty pharmacy growth in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45160757/the-cigna-group-reports-strong-first-quarter-2025-results-raises-2025-outlook" rel="noreferrer noopener">Evernorth Health Services</a>.
The company reported adjusted earnings of $6.74 per share, beating <a target="_blank" href="https://www.benzinga.com/25/05/45158861/cigna-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts" rel="noreferrer noopener">analysts&#8217; estimates of $6.35</a>.
Evernorth Health Services, including Pharmacy Benefit and Specialty and Care Services, reported first-quarter sales of $53.68 billion, up 16%.
<ul>
<li>Pharmacy Benefit Services sales reached $29.74 billion, 14% reflecting existing client relationships and new business growth.</li>
<li>&nbsp;Specialty and Care Services sales reached $23.94 billion, up 19%, reflecting strong specialty volume growth.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44627279/ftc-pauses-lawsuit-against-cvs-cigna-unitedhealths-pbms-amid-commissioner-shortage" rel="noreferrer noopener">FTC Pauses Lawsuit Against CVS, Cigna, UnitedHealth&#8217;s PBMs Amid Commissioner Shortage</a>
Cigna Healthcare segment sales increased 9% to $14.48 billion, primarily reflecting premium rate increases to cover expected increases in underlying medical costs.
<ul>
<li>The Cigna Healthcare medical cost ratio (MCR)&nbsp;was 82.2% for the first quarter of 2025, compared to 79.9% a year ago, primarily due to expected higher stop loss medical costs.</li>
<li>The Health Care Services Corporation&nbsp;(HCSC) transaction&nbsp;closed later than the company&#8217;s financial planning assumptions, increasing the first quarter Cigna Healthcare MCR&nbsp;as the Medicare businesses operate at a higher MCR&nbsp;than the rest of the portfolio.</li>
</ul>
Cigna ended the March quarter with total medical customers decreasing 6% from Dec. 31, 2024, to 18.04 million, primarily reflecting the impact of the HCSC transaction.
<ul>
<li>Excluding the impact of the HCSC transaction, total medical customers&nbsp;as of&nbsp;March 31, 2025, were consistent with&nbsp;December 31, 2024.</li>
</ul>
Total customer relationships stood at 182.2 million&nbsp;at&nbsp;March 31, 2025.
<ul>
<li>Excluding the impact of the HCSC transaction, total customer relationships increased 1% from Dec. 31, 2024.</li>
</ul>
Total pharmacy customers as of March 31, 2025, increased 3% from Dec. 31, 2024, to 122.3 million due to new sales and the continued expansion of relationships.
&#8220;Our strong first quarter results and increase in outlook for full-year earnings reflects the strength of our Evernorth Health Services and Cigna Healthcare growth platforms in a dynamic environment,&#8221; said David Cordani, chairman and CEO of the Cigna Group. 
Outlook:&nbsp;Cigna expects fiscal 2025 adjusted income per share of $29.60, <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43337308/cigna-stock-dives-on-q4-earnings-miss-we-are-taking-corrective-actions-to-address-these-near-term-pressures" rel="noreferrer noopener">up from $29.50</a> versus the consensus of $29.60
The company expects Evernorth&#8217;s adjusted income from operations (pre-tax of at least $7.2 billion, with at least $4.125 billion for Cigna Healthcare.
Cigna Healthcare Medical Care Ratio is expected to be between 83.2% to 84.2%.
CI Price Action: Cigna stock is up 2.93% at $344.99 during the premarket session at publication on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/05/45164086/chevron-q1-profit-drops-on-higher-costs-weak-international-margins" target="_blank" rel="noreferrer noopener">Chevron Q1 Profit Drops On Higher Costs, Weak International Margins</a></li>
</ul>
Photo: Shutterstock

Large Cap

Guidance

Health Care

Movers

Trading Ideas

Insurance

General

Cigna CEO Says Strong Q1 Earnings, Increased Outlook Reflect Strength In Growth Platforms

Wells Fargo analyst Andrew Bauch downgrades Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) from Overweight to Equal-Weight and lowers the price target from $95 to $50.

Downgrades

Wells Fargo Downgrades Block to Equal-Weight, Lowers Price Target to $50

Wells Fargo analyst Nathan Treybeck upgrades iRhythm Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) from Equal-Weight to Overweight and raises the price target from $104 to $130.

Upgrades

IRTC

Wells Fargo Upgrades iRhythm Technologies to Overweight, Raises Price Target to $130

Evercore ISI Group analyst Durgesh Chopra maintains Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) with a Outperform and raises the price target from $331 to $360.

Evercore ISI Group Maintains Outperform on Quanta Services, Raises Price Target to $360

<ul>
<li>AAPL</li>
<li>AMZN</li>
<li>TSLA</li>
<li>BULL</li>
<li>RDDT</li>
<li>GLD</li>
<li>MSTR</li>
<li>NVDA</li>
<li>DE</li>
<li>QQQ</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

BULL

MSTR

NVDA

RDDT

TSLA

Top 10 Trending Stocks On WallStreetBets As Of May 2, 2025 (Via Swaggy Stocks)

Evercore ISI Group analyst Steve Sakwa maintains Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) with a In-Line and raises the price target from $297 to $309.

Evercore ISI Group Maintains In-Line on Public Storage, Raises Price Target to $309

WIIM

Cooper-Standard Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

Cantor Fitzgerald analyst Deepak Mathivanan maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Overweight and raises the price target from $230 to $240.

Cantor Fitzgerald Maintains Overweight on Amazon.com, Raises Price Target to $240

FuboTV&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>)&nbsp;reported&nbsp;earnings for the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45162938/fubos-global-streaming-business-exceeded-subscriber-guidance-achieved-revenue-targets-in-q1-2025" rel="noreferrer noopener">first-quarter&nbsp;of 2025</a> on Friday. The stock price declined after the results.
Revenue of the sports-first live TV streaming platform grew 8.1%&nbsp;year over year&nbsp;to $405.96 million, marginally missing the&nbsp;analyst&nbsp;consensus estimate of $415.45 million.
Adjusted EPS loss of 2 cents beat the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst consensus estimate</a> of 9 cents.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/02/44042301/fubotv-projects-subscriber-fall-in-q1-after-q4-topline-growth-stock-tumbles" target="_blank" rel="noreferrer noopener">FuboTV Projects Subscriber Fall In Q1 After Q4 Topline Growth, Stock Tumbles</a>
The company's adjusted EBITDA margin loss stood at .3% versus 9.9% Y/Y. 
North America Streaming:&nbsp;Revenue grew 3.5% Y/Y to $407.9 million, as paid subscribers declined 2.7% Y/Y to 1.47 million. Average revenue per user (ARPU) rose 1.0% Y/Y to $85.37.
Rest of the World Streaming: Revenue was $8.4 million, a 0.4% Y/Y decline, and paid subscribers declined 10.9% Y/Y to 354,000. ARPU grew by 10.9% Y/Y to $7.76.
As of March 31, FuboTV held $327.8 million in cash and equivalents. The company used $61.99 million in free cash flow in the quarter, compared to $71.3 million from a year ago.
Outlook:&nbsp;FuboTV expects second-quarter North American revenue of $340 million–$350 million and ROW revenue of $6.5 million-$7.5 million versus consensus of&nbsp;$387.68 million <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst consensus estimate</a>.
Fubo expects 1.55 million-1.59 million total subscribers by the quarter.
It estimates North American subscribers to be 1.225 million-1.255 million, representing a 14% Y/Y decline at the midpoint.
It projects ROW 325,000-335,000 subscribers, representing a 17% Y/Y decline at the midpoint.
Price Action: Fubo stock traded lower by 7.51% at $2.71 premarket at last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/sports/25/04/44875151/fubo-extends-soccer-reign-in-canada-with-premier-league-renewal" target="_blank" rel="noreferrer noopener">Fubo Extends Soccer Reign In Canada With Premier League Renewal</a></li>
</ul>
Image: Logo courtesy of Fubo

FUBO

FuboTV Stock Drops After Q1 Subscriber Losses And Lower-Than-Expected Outlook

Press Releases

Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, LLP Investigates Claims on Behalf of Investors

Legal

Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates Claims on Behalf of Investors

ImmunityBio to Host Investor Day

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

Comments

ImmunityBio

Intérêt court

ImmunityBio (NASDAQ:IBRX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL